Forgot your password?
New User?
Remember me
banner banner

You are here:Home » Antibodies » Antibodies-Integrin » Anti -EDIL3 (Integrin-binding Protein DEL1, Developmentally-regulated Endothelial Cell Locus 1 Protein, EGF-like Repeat And Discoidin I-like Domain-containing Protein 3, DEL1)

Anti -EDIL3 (Integrin-binding Protein DEL1, Developmentally-regulated Endothelial Cell
Locus 1 Protein, EGF-like Repeat And Discoidin I-like Domain-containing Protein 3, DEL1)


  For pricing information, USA customers sign in.
  Outside USA? Please contact your distributor for pricing.


Clone Host Grade Applications
Polyclonal Sheep Affinity Purified B IC
EGF-like repeat and discoidin I-like domain-containing protein 3 (EDIL3; also Del-1 and integrin-binding DEL1) is a 52kD extracellular matrix protein that is expressed by endothelial tissues during embryonic vascular development (1). Human EDIL3 is synthesized as a precursor with a 16aa signal sequence and a 464aa mature chain. The mature chain is composed of three epidermal growth factor (EGF) repeats and two discoidin-I-like domains (1). The second EGF repeat contains an RGD motif (1). Splicing variants produce two isoforms for human EDIL3. Isoform 2 has an A->G substitution at aa66 and a deletion of aa67-76 found in isoform 1. Mature human EDIL3 shares 96aa sequence identity with mature mouse EDIL3. The RGD motif of EDIL3 binds av b5 integrin, which, in turn, leads to increased angiogenic transcription factor HoxD3 expression (2). HoxD3activates av b3 and uPA, resulting in the transformation of resting endothelial cells to an angiogenic state (2-4). EDIL3 becomes quiescent at the time of birth, and is no longer expressed in normal adult tissues. It has been found, however, re-expressed in a number of human tumors as well as in ischemic muscles and ischemic brain tissue, which may play an important role in adult angiogenesis (2, 5-6). EDIL3 promotes adherence and migration of endothelial cells, and acts as an endothelial cell survival agent through upregulation of Bcl-2 expression (7). Exogenous application of EDIL3 has been demonstrated to augment angiogenesis and improve blood flow and tissue function in murine models of hind-limb ischemia (6, 8), cardiac ischemia (9) and cerebral ischemia (2). EDIL3 has also been shown to be an endogenous inhibitor of inflammatory cell recruitment by interfering with the integrin LFA-1-dependent leukocyte-endothelial adhesion (10).
Catalog #E2204-30C
ApplicationsSuitable for use in Western Blot and Immunocytochemistry. Other applications not tested.
Recommended DilutionWestern Blot: 1ug/ml
Immunocytochemistry: 5-15ug/ml
Optimal dilutions to be determined by the researcher.
Storage and StabilityLyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Clone TypePolyclonal
ConcentrationNot determined
FormSupplied as a lyophilized powder in PBS, trehalose. Reconstitute with sterile PBS to 200ug/ml.
PurityPurified by immunoaffinity chromatography.
ImmunogenRecombinant corresponding to aa17-480 from human EDIL3 expressed in CHO cells (O43854).
SpecificityRecognizes human EDIL3.
Important NoteThis product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.

External Links